Skip to main content
. Author manuscript; available in PMC: 2020 Aug 25.
Published in final edited form as: Clin Cancer Res. 2018 Apr 10;24(14):3423–3432. doi: 10.1158/1078-0432.CCR-17-3406

Figure 4.

Figure 4.

Combination of PARP inhibitor and TMZ reduces metastatic lesion and prolongs overall survival. A, Cell viability test of SDHBKD cells under combination of TMZ and Ola showed Ola reduced the IC50 of TMZ. **, P < 0.01. B, BrdUrd incorporation test for MTT cells treated with TMZ and Ola showed Ola resulted less BrdUrd incorporation. Bar, 10 μm. C, In vivo bioluminescence assays of mice bearing MTT-SDHBKD-Luc cells under DMSO, Ola, TMZ or combination treatments. D, Quantification of the bioluminescence signals by the IVIS system. E, Survival curve of mice bearing MTT-SDHBKD-Luc cells under DMSO, Ola, TMZ or combination treatments (P = 0.0028). F, Histology and expression of γH2A.X and cleaved caspase-3 (cC3) in tumor sections from mice bearing MTT-SDHBKD-Luc cells under DMSO, Ola, TMZ or combination treatments. Bar, 10 μm.